JPRN-UMIN000032296
Recruiting
N/A
Effects of dapaglifrogine and metoformine in patients with type 2 diabetes:a randomized controlled study - Effects of dapaglifrogine and metoformine in patients with type 2 diabetes:a randomized controlled study
ConditionsType 2 diabetes
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Type 2 diabetes
- Sponsor
- Yokohama City University
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patients diagnosed with Type 1 diabetes or secondary forms of diabetes 2\)Patients with renal dysfunction (eGFR \<45ml/min/1\.73m2\) 3\)Patients with hepatic dysfunction(AST and/or ALT \>3X upper limit of normal) 4\)Patients with severe congestive heart failure, acute heart failure 5\)Patients who are taking steroid medication 6\) Patients with a history of diabetic ketoacidosis, diabetic coma during the last 6 months 7\)Patients with active malignant neoplasm 8\)Patients with severe infection or injury 9\)Patients with hypersensitivity to metoformine or dapaglifrogine 10\) Patients who are pregnant,lactating or willing to be pregnant during this study 11\) Patients who have taken SGLT2 or metoformine within 8 weeks prior to enroll, or who are already taking SGLT2 or metoformine 12\)Patients who are unable to obtain informed consent to this study 13\)Patients who are inadequacy of using this therapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 4
Comparative effects of dapagliflozin and metformin in obese diabetic patientsHealth Condition 1: E116- Type 2 diabetes mellitus with other specified complicationsCTRI/2023/11/059814 Shobana
Active, Not Recruiting
Phase 1
Effects of glucose-lowering interventions in pre-diabetesEUCTR2015-001552-30-DKSteno Diabetes Center A/S160
Not Yet Recruiting
Phase 3
A study on the effect of Dapagliflozin and Metformin combination on Insulin resistance and cardiovascular disease risk factors in subjects with type II diabetes mellitusHealth Condition 1: E118- Type 2 diabetes mellitus with unspecified complicationsCTRI/2023/10/059034S Abissha
Recruiting
N/A
Effects of Metformin, Sitagliptin and Empagliflozin as the first therapy for patients with type 2 diabetes: a randomized controlled study: MOSEL-first studyType2 diabetesJPRN-UMIN000035791Yokohama City University Medical Center99
Recruiting
Phase 3
Comparison of the effect of Metformin and Empagliflozin in treatment of prediabetic patients.Prediabetes.Abnormal glucose tolerance testR73.0IRCT20210926052602N1Kashan University of Medical Sciences100